<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18158420</article-id>
      <article-id pub-id-type="pmc">2636066</article-id>
      <article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_1_85_37590</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter To Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Surgery of basal cell carcinoma around the lacrimal canaliculus can be necessary after primary treatment with intralesional interferon alpha 2b</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Huerva</surname>
            <given-names>V</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mangues</surname>
            <given-names>I</given-names>
          </name>
          <degrees>PharmD</degrees>
        </contrib>
        <aff>Department of Ophthalmology (VH), Department of Pharmacy (IM), University Hospital Arnau de Vilanova. Avda Rovira Roure 80, 25198-Lleida, Spain. E-mail: <email>vhuerva@mixmail.com</email></aff>
      </contrib-group>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2008</year>
      </pub-date>
      <volume>56</volume>
      <issue>1</issue>
      <fpage seq="b">85</fpage>
      <lpage>86</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>Basal cell carcinoma (BCC) is the most common malignancy,
accounting for 90% of malignant eyelid tumors.<xref ref-type="bibr" rid="ref1">1</xref> Surgical
excision is the treatment of choice for periocular BCCs.
However, aggressive BCCs are therapeutically challenging
because their excision results in marked tissue loss and may
demand considerable oculoplastic and functional surgery.
Surgery for BCCs around the canaliculus is mutilating.
Interferon (INF) alpha 2b (Intron-A, Shering Corp) has been
proposed as a nonsurgical approach to treat BCC arising far
from the periocular zone.<xref ref-type="bibr" rid="ref2">2</xref> Interferons are proteins that inhibit
cell growth and cell differentiation and therefore exhibit an
antineoplastic action.<xref ref-type="bibr" rid="ref3">3</xref></p>
    <p>We used INF alpha 2b for management of a BCC below the
right inferior canaliculus in a 77-year-old man [<xref ref-type="fig" rid="F1">Fig. 1</xref>]. The lesion
was previously subjected to biopsy by his dermatologist with
histologic results of nodular BCC. Chronic epiphora was not
noted. Syringing of the canaliculus by means of a cannula of 25
G showed patency of them. Total surgical excision would have
caused a loss of the permeable canaliculus. Hence, intralesional
treatment with recombinant INF alone was proposed. After
informed consent was obtained, INF alpha 2b was injected three
times a week for three weeks with 1.5 x 10 (6) IU (0.15 ml) per
injection. The total dose received was 13.5 x 10 (6) IU. The lesion
persisted during the follow-up of six months [<xref ref-type="fig" rid="F2">Fig. 2</xref>]. Wide
surgical resection was then proposed. The histologic study of
the resected mass confirmed the persistence of nodular BCC.
During a year of follow-up no recurrences have been noticed.
However, a cicatricial medial ectropion was present.</p>
    <p>We used the same dosage as reported in the first study<xref ref-type="bibr" rid="ref3">3</xref>
which had 100% success rate for eight cutaneous BCCs after
two months of therapy. However, later studies reported
complete regression in only 67% of patients with cutaneous BCC
treated with intralesional INF alone.<xref ref-type="bibr" rid="ref4">4</xref> A 90.9% success rate has
been observed in the eyelids.<xref ref-type="bibr" rid="ref2">2</xref> In this study, the authors used
intralesional INF alpha 2b as an adjunctive treatment after the
resection of aggressive BCC and reconstruction. The patient in
the presented case had undergone a prior minor biopsy but not
a wide resection. It is possible that a wide resection followed
by intralesional INF could attain better satisfactory results in
BCC around the canaliculus. Surgical procedures may also
stimulate the immune system and prevent recurrences. We have
observed the absence of recurrence during follow-up in some
cases in which pathology studies revealed involved margins
after resection. In these cases, intralesional INF alpha 2b may
be a useful adjunctive treatment, as has been proposed.<xref ref-type="bibr" rid="ref2">2</xref> In
conclusion, intralesional INF alpha 2b cannot be the first choice
in the treatment of BCC around the canaliculus.</p>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cook</surname>
              <given-names>BE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Bartley</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmstead County, Minesota</article-title>
          <source>Ophthalmology</source>
          <year>1999</year>
          <volume>106</volume>
          <fpage>746</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">10201597</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fenton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moriarty</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids</article-title>
          <source>Acta Ophthalmol Scand</source>
          <year>2002</year>
          <volume>80</volume>
          <fpage>674</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">12485296</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenway</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Cornell</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Peets</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bordin</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Nagi</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Treatment of basal cell carcinoma with intralesional interferon</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1986</year>
          <volume>15</volume>
          <fpage>437</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">3760271</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chimenti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Peris</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Di Cristofaro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fargnoli</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Torlone</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Use of recombinant interferon alpha-2b in the treatment of basal cell carcinoma</article-title>
          <source>Dermatology</source>
          <year>1995</year>
          <volume>190</volume>
          <fpage>214</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">7599384</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>BCC below the inferior lacrimal canaliculus</p>
      </caption>
      <alt-text>Figure 1</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-85-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>BCC six months after treatment with intralesional interferon alpha 2b. The tumor persists. A nodular lesion is also present</p>
      </caption>
      <alt-text>Figure 2</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-85-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
